Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 865-876 of 4,306
Drug study icon
TerminatedNCT04825860

SEP-363856 for schizophrenia

This study was terminated in China, in Japan, in the Philippines, .... It is testing SEP-363856 for schizophrenia.

Multiple locations, including Beijing
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
China, Japan, Philippines, ...
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
Drug study icon
CompletedNCT04072354

Investigational Drug for schizophrenia

This study is completed in the United States, in Bulgaria, in Colombia, .... It is testing investigational Drug for schizophrenia.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 13 Years to 65 Years
Countries
United States, Bulgaria, Colombia, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
TerminatedNCT01328093

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Cerritos
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, France, Belgium, ...
Sponsor
Denovo Biopharma LLC
Condition
Schizophrenia
Behavioral study icon
CompletedNCT03260257

A Neurofeedback Intervention to Improve Working Memory in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In La Jolla
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of California, San Diego
Condition
Schizophrenia
Drug study icon
TerminatedNCT03900754

A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including San Francisco
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 70 Years
Countries
United States
Sponsor
VA Office of Research and Development
Condition
Schizophrenia
Drug study icon
CompletedNCT01626859

A Pharmacokinetic Study of MP-214 in people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Sakai
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 20 Years to 64 Years
Countries
Japan
Sponsor
Tanabe Pharma Corporation
Condition
Schizophrenia
Drug study icon
CompletedNCT04158687

Safety and Efficacy of CTP-692 for schizophrenia

This study is completed in the United States. It is testing Safety and Efficacy of CTP-692 for schizophrenia.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Concert Pharmaceuticals
Condition
Schizophrenia
Drug study icon
CompletedNCT01614899

A Phase III Study of SM-13496 (Lurasidone HCl) in people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Tokyo, Etc
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 74 Years
Countries
Japan, Malaysia, South Korea, ...
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.